Amerikanische Gesellschaft für Hirudotherapie

ກົມອາຫານ ແລະ ຢາ — ກະຊວງສາທາລະນະສຸກ

Laos FDD · Laos · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Laos' Food and Drug Department (Ministry of Health) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
Laos
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Lao PDR Law on Drugs and Medical Products (Law No. 38/NA, 2011, as amended)
  • Lao PDR national medical device regulatory framework
  • ASEAN Medical Device Directive (AMDD) harmonised frameworks where applicable

Prescriber Requirements

  • Lao Medical Council–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Laos FDD registration as applicable; Lao and English-language labelling. Standard cold-chain conditions, with logistical constraints typical of tropical Mekong distribution.

Import/Export Rules

Laos FDD and Department of Livestock and Fisheries clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Lao National Health Insurance (NHI) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. South-East Asian regulatory frameworks are progressively coordinating through the ASEAN Medical Device Directive (AMDD); whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.